Differential effects of anaemia and iron deficiency on long-term outcomes following transcatheter edge-to-edge repair in degenerative vs. secondary mitral regurgitation: results from a large single-center study.
Anaemia
Iron deficiency
Long-term outcome
Mitral regurgitation
TEER
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
08
01
2023
accepted:
17
04
2023
medline:
28
6
2023
pubmed:
2
5
2023
entrez:
2
5
2023
Statut:
ppublish
Résumé
Anaemia and iron deficiency (ID) are independently associated with adverse outcomes in patients with cardiovascular diseases, especially in those with heart failure. Here, we aimed to clarify the long-term effect of anaemia and ID on outcomes in patients undergoing transcatheter mitral edge-to-edge repair (TEER) for relevant mitral regurgitation (MR) as well as to relate these to the underlying MR aetiology. 833 patients (median age 77.1 years, 40.7% women, 63.3% secondary MR) treated by TEER between 09/2008 and 07/2019 were included and stratified according to baseline anaemia (hemoglobin < 12 g/dL in women and < 13 g/dL in men) or ID. Anaemia and ID were frequent with 61.6% and 68.1%, respectively. Anaemic patients had a lower functional status at baseline and were less likely to improve after TEER. In addition, anaemia was associated with all-cause mortality (hazard ratio [HR] = 1.68, 95% confidence interval [CI] 1.36-2.07, p < 0.001) and the composite endpoint of death or heart failure (HF) rehospitalization (HR = 1.30, 95% CI 1.10-1.54, p = 0.002). In contrast, ID was not associated with either all-cause mortality or the composite endpoint of death or HF rehospitalization. Patients undergoing TEER have high rates of both anaemia and ID. However, anaemia is associated with worse functional baseline status and post-interventional improvements compared to ID. Furthermore, anaemia is linked to higher rates of mortality and HF rehospitalization, particularly in those with secondary MR.
Sections du résumé
BACKGROUND
BACKGROUND
Anaemia and iron deficiency (ID) are independently associated with adverse outcomes in patients with cardiovascular diseases, especially in those with heart failure. Here, we aimed to clarify the long-term effect of anaemia and ID on outcomes in patients undergoing transcatheter mitral edge-to-edge repair (TEER) for relevant mitral regurgitation (MR) as well as to relate these to the underlying MR aetiology.
METHODS
METHODS
833 patients (median age 77.1 years, 40.7% women, 63.3% secondary MR) treated by TEER between 09/2008 and 07/2019 were included and stratified according to baseline anaemia (hemoglobin < 12 g/dL in women and < 13 g/dL in men) or ID.
RESULTS
RESULTS
Anaemia and ID were frequent with 61.6% and 68.1%, respectively. Anaemic patients had a lower functional status at baseline and were less likely to improve after TEER. In addition, anaemia was associated with all-cause mortality (hazard ratio [HR] = 1.68, 95% confidence interval [CI] 1.36-2.07, p < 0.001) and the composite endpoint of death or heart failure (HF) rehospitalization (HR = 1.30, 95% CI 1.10-1.54, p = 0.002). In contrast, ID was not associated with either all-cause mortality or the composite endpoint of death or HF rehospitalization.
CONCLUSION
CONCLUSIONS
Patients undergoing TEER have high rates of both anaemia and ID. However, anaemia is associated with worse functional baseline status and post-interventional improvements compared to ID. Furthermore, anaemia is linked to higher rates of mortality and HF rehospitalization, particularly in those with secondary MR.
Identifiants
pubmed: 37129668
doi: 10.1007/s00392-023-02210-7
pii: 10.1007/s00392-023-02210-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
967-980Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Glower DD, Kar S, Trento A, Lim DS, Bajwa T, Quesada R, Whitlow PL, Rinaldi MJ, Grayburn P, Mack MJ, Mauri L, McCarthy PM, Feldman T (2014) Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol 64(2):172–181. https://doi.org/10.1016/J.JACC.2013.12.062
doi: 10.1016/J.JACC.2013.12.062
pubmed: 25011722
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D et al (2021) 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur J Cardio Thoracic Surg 60(4):727–800. https://doi.org/10.1093/EJCTS/EZAB389
doi: 10.1093/EJCTS/EZAB389
Koell B, Orban M, Weimann J, Kassar M, Karam N, Neuss M, Petrescu A, Iliadis C, Unterhuber M, Adamo M, Giannini C, Melica B, Ludwig S, Massberg S, Praz F, Pfister R, Thiele H, von Bardeleben RS, Baldus S, Kalbacher D (2021) Outcomes stratified by adapted inclusion criteria after mitral edge-to-edge repair. J Am Coll Cardiol 78(24):2408–2421. https://doi.org/10.1016/J.JACC.2021.10.011
doi: 10.1016/J.JACC.2021.10.011
pubmed: 34886961
Iliadis C, Lee S, Kuhr K, Metze C, Matzik AS, Michels G, Rudolph V, Baldus S, Pfister R (2017) Functional status and quality of life after transcatheter mitral valve repair: a prospective cohort study and systematic review. Clin Res Cardiol 106(12):1005–1017. https://doi.org/10.1007/S00392-017-1150-X
doi: 10.1007/S00392-017-1150-X
pubmed: 28785812
Kalbacher D, Schäfer U, Bardeleben RS, Eggebrecht H, Sievert H, Nickenig G, Butter C, May AE, Bekeredjian R, Ouarrak T, Kuck KH, Plicht B, Zahn R, Baldus S, Ince H, Schillinger W, Boekstegers P, Senges J, Lubos E (2019) Long-term outcome, survival and predictors of mortality after MitraClip therapy: results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry. Int J Cardiol 277:35–41. https://doi.org/10.1016/J.IJCARD.2018.08.023
doi: 10.1016/J.IJCARD.2018.08.023
pubmed: 30153994
Engoren M, Schwann TA, Habib RH, Neill SN, Vance JL, Likosky DS (2014) The independent effects of anemia and transfusion on mortality after coronary artery bypass. Ann Thorac Surg 97(2):514–520. https://doi.org/10.1016/J.ATHORACSUR.2013.09.019
doi: 10.1016/J.ATHORACSUR.2013.09.019
pubmed: 24206967
von Haehling S, Schefold JC, Hodoscek LM, Doehner W, Mannaa M, Anker SD, Lainscak M (2009) Anaemia is an independent predictor of death in patients hospitalized for acute heart failure. Clin Res Cardiol 99(2):107–113. https://doi.org/10.1007/S00392-009-0092-3
doi: 10.1007/S00392-009-0092-3
Ergatoudes C, Schaufelberger M, Andersson B, Pivodic A, Dahlström U, Michael Fu (2019) Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry. Clin Res Cardiol 108(9):1025–1033. https://doi.org/10.1007/S00392-019-01430-0/FIGURES/4
doi: 10.1007/S00392-019-01430-0/FIGURES/4
pubmed: 30788622
pmcid: 6694087
Backhaus T, Fach A, Schmucker J, Fiehn E, Garstka D, Stehmeier J, Hambrecht R, Wienbergen H (2017) Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute ST-segment elevation myocardial infarction: results from the Bremen STEMI Registry. Clin Res Cardiol 107(5):371–379. https://doi.org/10.1007/S00392-017-1192-0
doi: 10.1007/S00392-017-1192-0
pubmed: 29230546
Takagi H, Hari Y, Kawai N, Ando T (2019) Meta-analysis of impact of anemia and hemoglobin level on survival after transcatheter aortic valve implantation. Am J Cardiol 123(2):306–314. https://doi.org/10.1016/J.AMJCARD.2018.09.042
doi: 10.1016/J.AMJCARD.2018.09.042
pubmed: 30401487
Stauder R, Valent P, Theurl I (2018) Anemia at older age: etiologies, clinical implications, and management. Blood 131(5):505–514. https://doi.org/10.1182/BLOOD-2017-07-746446
doi: 10.1182/BLOOD-2017-07-746446
pubmed: 29141943
Cleland JGF, Zhang J, Pellicori P, Dicken B, Dierckx R, Shoaib A, Wong K, Rigby A, Goode K, Clark AL (2016) Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol 1(5):53947. https://doi.org/10.1001/JAMACARDIO.2016.1161
doi: 10.1001/JAMACARDIO.2016.1161
Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, Inciardi RM, Clark AL (2022) Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol 79(4):341–351. https://doi.org/10.1016/J.JACC.2021.11.039
doi: 10.1016/J.JACC.2021.11.039
pubmed: 35086656
Hellhammer K, Balzer J, Zeus T, Rammos C, Niebel S, Kubatz L, Wagstaff R, Kelm M, Rassaf T (2015) Percutaneous mitral valve repair using the MitraClip system in patients with anemia. Int J Cardiol 184(1):399–404. https://doi.org/10.1016/J.IJCARD.2015.02.081
doi: 10.1016/J.IJCARD.2015.02.081
pubmed: 25746494
Kaneko H, Neuss M, Okamoto M, Weissenborn J, Butter C (2018) Impact of preprocedural anemia on outcomes of patients with mitral regurgitation who underwent MitraClip implantation. Am J Cardiol 122(5):859–865. https://doi.org/10.1016/J.AMJCARD.2018.05.028
doi: 10.1016/J.AMJCARD.2018.05.028
pubmed: 30064861
Iliadis C, Metze C, Körber MI, Baldus S, Pfister R (2020) Association of iron deficiency, anaemia, and functional outcomes in patients undergoing edge-to-edge mitral valve repair. ESC Heart Fail 7(5):2379–2387. https://doi.org/10.1002/EHF2.12778
doi: 10.1002/EHF2.12778
pubmed: 32621385
pmcid: 7524056
Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16(7):777–802. https://doi.org/10.1016/S0894-7317(03)00335-3
doi: 10.1016/S0894-7317(03)00335-3
pubmed: 12835667
Foster E, Wasserman HS, Gray W, Homma S, di Tullio MR, Rodriguez L, Stewart WJ, Whitlow P, Block P, Martin R, Merlino J, Herrmann HC, Wiegers SE, Silvestry FE, Hamilton A, Zunamon A, Kraybill K, Gerber IL, Weeks SG, Feldman T (2007) Quantitative assessment of severity of mitral regurgitation by serial echocardiography in a multicenter clinical trial of percutaneous mitral valve repair. Am J Cardiol 100(10):1577–1583. https://doi.org/10.1016/J.AMJCARD.2007.06.066
doi: 10.1016/J.AMJCARD.2007.06.066
pubmed: 17996523
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/EURHEARTJ/EHAB368
doi: 10.1093/EURHEARTJ/EHAB368
pubmed: 34447992
Raposeiras-Roubin S, Adamo M, Freixa X, Benito-González DAT, Montefusco A, Pascual I et al (2022) A score to assess mortality after percutaneous mitral valve repair. J Am Coll Cardiol 79(6):562–573. https://doi.org/10.1016/J.JACC.2021.11
doi: 10.1016/J.JACC.2021.11
pubmed: 35144748
Schrage B, Rübsamen N, Schulz A, Münzel T, Pfeiffer N, Wild PS, Beutel M et al (2020) Iron deficiency is a common disorder in general population and independently predicts all-cause mortality: results from the Gutenberg Health Study. Clin Res Cardiol 109(11):1352–1357. https://doi.org/10.1007/S00392-020-01631-Y/TABLES/3
doi: 10.1007/S00392-020-01631-Y/TABLES/3
pubmed: 32215702
pmcid: 7588396
Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA (2013) Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. https://doi.org/10.1016/J.AHJ.2013.01.017
doi: 10.1016/J.AHJ.2013.01.017
pubmed: 23537975
Bekfani T, Pellicori P, Morris D, Ebner N, Valentova M, Sandek A, Doehner W et al (2018) Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. Clin Res Cardiol 108(2):203–211. https://doi.org/10.1007/S00392-018-1344-X
doi: 10.1007/S00392-018-1344-X
pubmed: 30051186
Wienbergen H, Pfister O, Hochadel M, Fach A, Backhaus T, Bruder O, Remppis BA et al (2019) Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study. Clin Res Cardiol 108(1):93–100. https://doi.org/10.1007/S00392-018-1327-Y
doi: 10.1007/S00392-018-1327-Y
pubmed: 30003365
Graham FJ, Pellicori P, Ford I, Petrie MC, Kalra PR, Cleland JGF (2021) Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clin Res Cardiol 110(8):1299–1307. https://doi.org/10.1007/S00392-021-018
doi: 10.1007/S00392-021-018
pubmed: 33755777
pmcid: 8318946
Mazer CD, Whitlock RP, Fergusson DA, Hall J, Belley-Cote E, Connolly K, Khanykin B et al (2017) Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med 377(22):2133–2144. https://doi.org/10.1056/NEJMOA1711818
doi: 10.1056/NEJMOA1711818
pubmed: 29130845